Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
NEW YORK, April 01, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq:RMTI) between September 9, 2015 and February 29, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Rockwell securities between September 9, 2015 and February 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/rockwell-medical.
The complaint alleges that the Company failed to disclose that: (1) Rockwell’s main product offering for Triferic has not yet been approved by the FDA; and (2) Rockwell is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement.
If you suffered a loss in Rockwell you have until May 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/rockwell-medical.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
